You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Breakdown of patients included in the study

From: Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

  Male Female Overall
Average % SD Average % SD Average % SD
Population N = 581 N = 676 N = 1,257
Age 76.55 9.47 80.01 8.48 78.41 9.11
Age groups       
27–74 years 33.22   19.82   26.01  
75–80 years 29.78   26.92   28.24  
81–84 years 17.90   24.11   21.20  
85–99 years 19.10   29.14   24.50  
Visits* 13.93 6.58 14.22 6.51 14.08 6.54
Percentage of visits with incident* 19.11 18.93 19.35 18.53 19.24 18.71
INR 2.50 0.40 2.53 0.36 2.52 0.38
Average weekly dose of VKA (mg) 12.93 6.46 11.99 5.96 12.43 6.21
Patients participating in the study for over 5 months N = 435 N = 509 N = 944
Age 76.37 9.27 79.41 8.32 78.01 8.90
Age groups       
27–74 years 34.94   22.40   28.18  
75–80 years 29.43   28.49   28.92  
81–84 years 19.31   22.59   21.08  
85–99 years 16.32   26.52   21.82  
Visits* 16.59 5.03 16.78 4.98 16.69 5.00
Percentage of visits with incident* 15.88 13.71 17.17 14.24 16.58 14.01
INR 2.50 0.25 2.53 0.25 2.52 0.25
Average weekly dose of VKA (mg) 12.83 6.55 12.05 5.96 12.41 6.25
  1. Note: Stars denote statistically significant differences between the sample and the population at 95% confidence.